May 5 (Reuters) - Novozymes A/S NSISb.CO:
2026 OUTLOOK CONFIRMED
Q1 ORGANIC GROWTH 7% VERSUS 6.2% SEEN IN COMPANY-PROVIDED CONSENSUS
Q1 ADJUSTED EBITDA MARGIN 37.8% VERSUS 37.4% SEEN IN IN COMPANY-CONSENSUS
Q1 NET REVENUE EUR 1,119.3 MILLION VERSUS EUR 1,111.4 MILLION SEEN IN COMPANY-PROVIDED CONSENSUS
Q1 ADJUSTED EBITDA EUR 423.0 MILLION VERSUS EUR 415.2 MILLION SEEN IN COMPANY-CONSENSUS
RELEVANCE AND DEMAND FOR BIOSOLUTIONS CONTINUE TO GROW
ON MIDDLE EAST SITUATION: WE CURRENTLY DO NOT EXPECT A MATERIAL IMPACT ON OUR OUTLOOK
Source text: ID:nGNE2cqsWT
Further company coverage: [NSISb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))